Wockhardt Ltd

Wockhardt announced that ICRA has upgraded the credit ratings to BBB/ A3+ and revised the outlook from stable to positive for various debt facilities availed by the company. Powered by Capital Market - Live

Wockhardt has allotted 6,600 equity shares under ESOS on 21 August 2025. In view of the above, the paid-up equity share capital of the Company will increase from Rs. 81,24,27,845/- consisting of 16,24,85,569 equity shares of Rs.5/- each to Rs.81,24,60,845/- consisting of 16,24,92,169 equity shares of Rs.5/- each.Powered by Capital Market - Live

Net Loss of Wockhardt reported to Rs 90.00 crore in the quarter ended June 2025 as against net loss of Rs 14.00 crore during the previous quarter ended June 2024. Sales declined 0.14% to Rs 738.00 crore in the quarter ended June 2025 as against Rs 739.00 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales738.00739.00 0 OPM %9.7612.31 - PBDT44.0048.00 -8 PBT-12.00-6.00 -100 NP-90.00-14.00 -543 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live

A clinically challenging case involving Wockhardt's novel antibiotic Zaynich' was recently published in the July 17, 2025 issue of the Journal of Antimicrobial Chemotherapy - AMR, a leading publication by the British Society for Antimicrobial Chemotherapy. The publication details the successful use of Zaynich', a combination of Zidebactam and Cefepime, in treating a critically ill U.S. liver transplant patient suffering from a pan-drug resistant infection'an infection resistant to all available antibiotics in the United States. This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Notably, this patient was infected with two different pathogens - Pseudomonas and Klebsiella, both resistant to all the recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam. The case report detailed the results of genetic analysis of bacterial DNA and determined that Pseudomonas and Klebsiella harbored 4 distinct resistance mechanisms each leading to pan-drug resistance. Initially, the patient was treated for 10 weeks with cefiderocol and eravacycline (a novel tetracycline antibiotic), but the infection persisted, and the Pseudomonas strain became resistant to cefiderocol. The patient continued to suffer from fever and chills, and imaging tests showed new abscesses in the liver ' clear signs that the infection was not under control. Given the high risk of transplant failure due to these MDR infections, a multidisciplinary team, including microbiologists, infectious disease experts, oncologists, and transplant surgeons, sought emergency access to Zaynich'. The antibiotic was administered for 14 days around the time of the liver transplant. The results were remarkable - within 11 days, the patient improved clinically and transferred from ICU to regular floor, and follow-up imaging showed no signs of active infection. Importantly, the patient remained infection-free even after six weeks of completing treatment with Zaynich', making liver transplant successful and allowing doctors to safely resume chemotherapy for the underlying cancer. The authors highlighted the role of Zaynich' as a potential treatment option for extensively drug resistant infections with extremely limited/no treatment options. Zaynich' is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial, which will support its marketing authorization across international markets. Prior to this, multiple Phase I clinical pharmacology studies involving the Zidebactam/Cefepime combination were successfully conducted in the United States. Zaynich' has also completed a multi-indication clinical study in India, specifically targeting carbapenem-resistant infections. To date, more than 50 patients in India and the U.S. suffering from highly resistant infections have been treated with Zaynich' under compassionate use programs. Powered by Capital Market - Live

Wockhardt announced that the 26th Annual General Meeting(AGM) of the company will be held on 8 August 2025.Powered by Capital Market - Live

The move is aimed at realigning focus toward high-impact areas, including novel antibiotic drug discovery and biologics-led insulin solutions. The decision comes after its US generics unit posted a $8 million loss in FY25. To facilitate the exit, Wockhardt filed for voluntary liquidation of its US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, under Chapter 7 of the US Bankruptcy Code, effective 11 July 2025. The company says this decision enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas. The company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance. Wockhardt is a research based global pharmaceutical and biotech company. On a consolidated basis, Wockhardt reported net loss of Rs 25 crore in Q4 March 2025 as against net loss of Rs 169 crore in Q4 March 2024. Net sales rose 6.14% YoY to Rs 743 crore in Q4 March 2025. Powered by Capital Market - Live

Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio. This strategic reset aligns with Wockhardt's sharpened focus on building a future-ready business anchored in two key pillars: 1. New Antibiotic Drug Discovery - where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets. 2. Biologicals Portfolio in Insulin - leveraging advanced technologies to address critical unmet needs in diabetes care. Over the past several years, Wockhardt's US generics business has been incurring losses. In FY 2025 alone, the generics business incurred a loss of nearly USD 8 million. Following a comprehensive strategic review, the Company has concluded that continuing in this segment would detract from its broader innovation agenda. Accordingly, Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware which are wholly owned subsidiaries of Wockhardt Bio AG. This decision, effective 11 July 2025, enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas. By stepping away from the commoditized generics space, Wockhardt is positioning itself to create long-term value through innovation, scientific excellence, and sustainable profitability. The Company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance.Powered by Capital Market - Live

Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales743.00700.00 6 3012.002798.00 8 OPM %8.61-8.43 -13.053.25 - PBDT31.00-78.00 LP 201.00-131.00 LP PBT-22.00-136.00 84 -16.00-354.00 95 NP-25.00-169.00 85 -47.00-463.00 90 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live